Summary

Middle East DNA Synthesis Market Trends

The Middle East DNA synthesis market size was estimated at USD 44.7 million in 2024 and is projected to reach USD 143.3 million by 2033, growing at a CAGR of 14.29% from 2025 to 2033. Increasing investments in biotechnology, developing research initiatives in genomics, and rising demand for synthetic biology applications across healthcare and industrial sectors in the region drive this growth.

Rising academic and clinical research activity is a significant driver of the DNA synthesis industry in the Middle East. Over the past decade, the region has witnessed substantial growth in research infrastructure, with governments and private stakeholders investing in universities, research centers, and teaching hospitals. Institutions across countries such as Saudi Arabia, the UAE, and Qatar increasingly prioritize genetic and molecular biology research, leading to heightened demand for synthetic DNA tools. These tools are essential for a wide range of applications, including gene editing, cloning, and the development of diagnostic assays. The increased availability of funding for R&D, along with collaborations with international research bodies, is further encouraging the adoption of DNA synthesis technologies in academic settings.

Moreover, the clinical research landscape in the Middle East is expanding, especially in precision medicine and translational genomics. Hospitals and medical research institutions are undertaking more clinical trials and biomarker discovery initiatives to understand disease mechanisms and develop targeted therapies. These efforts often rely heavily on synthetic oligonucleotides and gene constructs, further driving market demand. Moreover, national genomics initiatives such as the Qatar Genome Program and the Saudi Human Genome Program generate large volumes of genetic data, requiring synthetic DNA for validation, analysis, and downstream applications. Integrating genomics into healthcare and clinical decision-making is accelerating the use of DNA synthesis technologies across the region’s medical research ecosystem.

Increasing Focus on Precision Medicine and Genomics

The increasing focus on precision medicine and genomics is emerging as a key driver of the DNA synthesis industry in the Middle East. As countries in the region strive to modernize their healthcare systems, there is a growing emphasis on personalized treatment approaches that cater to the unique genetic profiles of individuals. For instance, in February 2025, a study in Nature Genetics highlighted the Greater Middle East's potential as a global genomics hub for rare diseases, despite data challenges and underutilized genetic diversity. Governments and healthcare institutions are investing in genome sequencing, molecular diagnostics, and genetic screening programs to support early diagnosis and targeted therapies. DNA synthesis plays a crucial role in these initiatives by enabling the design and production of synthetic genes, oligonucleotides, and other molecular tools used in genomic testing, biomarker validation, and developing precision drugs.

National genomics programs have accelerated this trend by driving large-scale demand for synthetic DNA. Initiatives such as the Saudi Human Genome Program and the Qatar Genome Program are focused on building comprehensive genomic databases to inform population-wide health strategies. These projects require vast amounts of synthetic DNA for sequencing validation, probe development, and functional genomic studies. Moreover, integrating genomic data into electronic health records and clinical workflows encourages hospitals and diagnostic labs to adopt DNA synthesis technologies for routine applications. As precision medicine becomes a central component of regional healthcare agendas, the need for scalable, reliable, and cost-effective DNA synthesis solutions is expected to grow significantly, making it a cornerstone of the market's expansion in the Middle East.

Middle East DNA Synthesis Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the Middle East DNA synthesis market report based on the service type, application, end use, and country.

• Service Type Outlook (Revenue, USD Million, 2021 - 2033)
• Oligonucleotide Synthesis
o By Type
o Standard Oligonucleotide Synthesis
o Custom Oligonucleotide Synthesis
o By Length
o Less than 50 nt
o 51-100 nt
o 101-150 nt
o More than 150 nt
• Gene Synthesis
o By Type
o Custom Gene Synthesis
o Gene Library Synthesis
o By Length
o Less than 500 nt
o 501-1000 nt
o 1001-1500 nt
o 1501-2000 nt
o 2001-2500 nt
o More than 2500 nt
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Research and Development
o Oligonucleotide Synthesis
o PCR
o NGS
o CRISPR
o Cloning and Mutagenesis
o Others
• Gene Synthesis
o Synthetic Biology
o Vaccine Development
o Genetic Engineering
o Others
• Diagnostics
• Therapeutics
o RNAi Therapies
o Antisense Oligonucleotide-based Therapies
o Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceutical and Diagnostics Companies
• Academic and Research Institutes
• Contract Research Organizations
• Country Outlook (Revenue, USD Million, 2021 - 2033)
• Saudi Arabia
• UAE
• Kuwait
• Qatar
• Oman
• Rest of Middle East

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Service Type
1.2.2. Application
1.2.3. End-use
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. Middle East DNA Synthesis Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising academic and clinical research activities
3.2.1.2. Increasing focus on precision medicine and genomics
3.2.2. Market restraint analysis
3.2.2.1. Limited local manufacturing and infrastructure
3.2.2.2. Regulatory and ethical uncertainty
3.3. Middle East DNA synthesis Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
Chapter 4. Middle East DNA Synthesis Market: Service Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Middle East DNA Synthesis Market Service Type Movement Analysis
4.3. Middle East DNA Synthesis Market Size & Trend Analysis, by Service Type, 2021 to 2033 (USD Million)
4.4. Oligonucleotide synthesis
4.4.1. Oligonucleotides synthesis market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.1. Standard oligonucleotides synthesis
4.4.1.1.1. Standard oligonucleotides synthesis market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.2. Custom oligonucleotide synthesis
4.4.1.2.1. Custom oligonucleotides synthesis market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.3. Less than 50nt
4.4.1.3.1. Less than 50nt market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.4. 51-100nt
4.4.1.4.1. 51-100nt market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.5. 101-150nt
4.4.1.5.1. 101-150nt synthesis market estimates and forecasts, 2021 to 2033 (USD Million)
4.4.1.6. More than 150nt
4.4.1.6.1. More than 150nt synthesis market estimates and forecasts, 2021 to 2033 (USD Million)
4.5. Gene synthesis
4.5.1. Gene synthesis market estimates and forecasts, 2021 to 2033 (USD Million)
4.5.1.1. Custom gene synthesis
4.5.1.1.1. Custom gene synthesis market estimates and forecasts, 2021 to 2033 (USD Million)
4.5.1.2. Gene library synthesis
4.5.1.2.1. Gene library synthesis market estimates and forecasts, 2021 to 2033 (USD Million)
4.5.1.3. Less than 500nt
4.5.1.3.1. Less than 500nt market estimates and forecasts, 2021 to 2033 (USD Million)
4.5.1.4. 501-1000nt
4.5.1.4.1. 501-1000nt market estimates and forecasts, 2021 to 2033 (USD Million)
4.5.1.5. 1001-1500nt
4.5.1.5.1. 1001-1500nt synthesis market estimates and forecasts, 2021 to 2033 (USD Million)
4.5.1.6. 1501-2000nt
4.5.1.6.1. 1501-2000nt synthesis market estimates and forecasts, 2021 to 2033 (USD Million)
4.5.1.7. 2001-2500nt
4.5.1.7.1. 2001-2500nt synthesis market estimates and forecasts, 2021 to 2033 (USD Million)
4.5.1.8. More than 2500nt
4.5.1.8.1. More than 2500nt synthesis market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 5. Middle East DNA Synthesis Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Middle East DNA Synthesis Market Application Movement Analysis
5.3. Middle East DNA Synthesis Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Research & Development
5.4.1. Research & development market estimates and forecasts, 2021 to 2033 (USD Million)
5.4.2. Oligonucleotide synthesis
5.4.2.1. Oligonucleotide synthesis tumors market estimates and forecasts, 2021 to 2033 (USD Million)
5.4.2.2. PCR
5.4.2.2.1. PCR synthesis tumors market estimates and forecasts, 2021 to 2033 (USD Million)
5.4.2.3. NGS
5.4.2.3.1. NGS synthesis tumors market estimates and forecasts, 2021 to 2033 (USD Million)
5.4.2.4. CRISPR
5.4.2.4.1. CRISPR synthesis tumors market estimates and forecasts, 2021 to 2033 (USD Million)
5.4.2.5. Cloning and mutagenesis
5.4.2.5.1. Cloning and mutagenesis synthesis tumors market estimates and forecasts, 2021 to 2033 (USD Million)
5.4.2.6. Others
5.4.2.6.1. Others synthesis tumors market estimates and forecasts, 2021 to 2033 (USD Million)
5.4.3. Gene synthesis
5.4.3.1. Gene synthesis market estimates and forecasts, 2021 to 2033 (USD Million)
5.4.3.2. Synthetic biology
5.4.3.2.1. Synthetic biology tumors market estimates and forecasts, 2021 to 2033 (USD Million)
5.4.3.3. Vaccine development
5.4.3.3.1. Vaccine development synthesis tumors market estimates and forecasts, 2021 to 2033 (USD Million)
5.4.3.4. Genetic engineering
5.4.3.4.1. Genetic engineering synthesis tumors market estimates and forecasts, 2021 to 2033 (USD Million)
5.4.3.5. Others
5.4.3.5.1. Others synthesis tumors market estimates and forecasts, 2021 to 2033 (USD Million)
5.5. Diagnostics
5.5.1. Diagnostics market estimates and forecasts, 2021 to 2033 (USD Million)
5.6. Therapeutics
5.6.1. Therapeutics market estimates and forecasts, 2021 to 2033 (USD Million)
5.6.2. RNAi therapies
5.6.2.1. RNAi therapies market estimates and forecasts, 2021 to 2033 (USD Million)
5.6.3. Antisense and oligonucleotide-based therapies
5.6.3.1. Antisense and oligonucleotide-based therapies market estimates and forecasts, 2021 to 2033 (USD Million)
5.6.4. Others
5.6.4.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 6. Middle East DNA Synthesis Market: End-Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Middle East DNA Synthesis Market End-use Movement Analysis
6.3. Middle East DNA Synthesis Market Size & Trend Analysis, by End-use, 2021 to 2033 (USD Million)
6.4. Biopharmaceutical & Diagnostic Companies
6.4.1. Biopharmaceutical & diagnostic companies market estimates and forecasts, 2021 to 2033 (USD Million)
6.5. Academic & Research Institutes
6.5.1. Academic & research institutes market estimates and forecasts, 2021 to 2033 (USD Million)
6.6. Contract Research Organizations
6.6.1. Contract Research Organizations market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 7. Middle East DNA Synthesis Market: Regional Estimates & Trend Analysis
7.1. Country Market Share Analysis, 2024 & 2033
7.2. Country Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.4. Middle East
7.4.1. Saudi Arabia
7.4.1.1. Key country dynamics
7.4.1.2. Competitive scenario
7.4.1.3. Regulatory landscape
7.4.1.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
7.4.2. UAE
7.4.2.1. Key country dynamics
7.4.2.2. Competitive scenario
7.4.2.3. Regulatory landscape
7.4.2.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
7.4.3. Kuwait
7.4.3.1. Key country dynamics
7.4.3.2. Competitive scenario
7.4.3.3. Regulatory landscape
7.4.3.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)
7.4.4. Qatar
7.4.4.1. Key country dynamics
7.4.4.2. Competitive scenario
7.4.4.3. Regulatory landscape
7.4.4.4. Qatar market estimates and forecasts, 2021 to 2033 (USD Million)
7.4.5. Oman
7.4.5.1. Key country dynamics
7.4.5.2. Competitive scenario
7.4.5.3. Regulatory landscape
7.4.5.4. Oman market estimates and forecasts, 2021 to 2033 (USD Million)
7.4.6. Rest of Middle East
7.4.6.1. Key country dynamics
7.4.6.2. Competitive scenario
7.4.6.3. Regulatory landscape
7.4.6.4. Rest of Middle East market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company/Competition Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2024
8.4. Company Profiles/Listing
8.4.1. Thermo Fisher Scientific, Inc
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Service benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Eurofins Scientific
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Service benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Integrated DNA Technologies, Inc.
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Service benchmarking
8.4.3.4. Strategic initiatives
8.4.4. LGC Biosearch Technologies
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Service benchmarking
8.4.4.4. Strategic initiatives
8.4.5. AlGenome International
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Service benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Quintara Biosciences
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Service benchmarking
8.4.6.4. Strategic initiatives
8.4.7. DNA Script
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Service benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Agilent Technologies
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Service benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Twist Bioscience
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Service benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Bio‑Synthesis Inc.
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Service benchmarking
8.4.10.4. Strategic initiatives